Clovis Oncology ( CLVS) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the U.S., Europe and additional international markets. This stock is trading up 2.6% at $21.15 in recent trading. Today's Volume: 52,000 Average Volume: 74,313 Volume % Change: 50% >>22 Biopharma Stocks With Breakout Potential in 2012 From a technical perspective, CLVS is bouncing modestly here right off its 50-day moving average of $18.32 with decent volume. This move is quickly pushing CLVS within range of a near-term breakout trade. That trade will hit once CLVS takes out some near-term overhead resistance at $21.40 with high volume. Traders should now look for long-biased trades in CLVS as long as its trending above its 50-day, and then once it sustains a move or close above $21.40 with volume that's near or above 74,313 shares. If that breakout triggers soon, then CLVS will have a great chance of re-testing or possibly taking out its next major overhead resistance level at $23.42.
Susser Petroleum (SUSP) stock is soaring Monday after Energy Transfer Partners (ETP) agreed to acquire Susser Holdings Corporation (SUSS). ETP will own general partner (GP) interest and incentive distribution rights (IDRs) in its unit Susser Petroleum.